1. Home
  2. CAPR vs CDNL Comparison

CAPR vs CDNL Comparison

Compare CAPR & CDNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$19.50

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

CDNL

Cardinal Infrastructure Group Inc. Class A Common Stock

N/A

Current Price

$69.25

Market Cap

1.5B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CAPR
CDNL
Founded
2005
2013
Country
United States
United States
Employees
N/A
1480
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
CAPR
CDNL
Price
$19.50
$69.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
3
Target Price
$44.63
$38.00
AVG Volume (30 Days)
1.7M
872.1K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$50.30
Revenue Next Year
$3.31
$8.41
P/E Ratio
N/A
$0.01
Revenue Growth
N/A
N/A
52 Week Low
$4.30
$21.98
52 Week High
$40.37
$96.40

Technical Indicators

Market Signals
Indicator
CAPR
CDNL
Relative Strength Index (RSI) 28.96 46.79
Support Level $5.25 $63.77
Resistance Level $30.39 $96.40
Average True Range (ATR) 1.33 7.19
MACD -0.26 -1.80
Stochastic Oscillator 16.93 15.38

Price Performance

Historical Comparison
CAPR
CDNL

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About CDNL Cardinal Infrastructure Group Inc. Class A Common Stock

Cardinal Infrastructure Group Inc provides a comprehensive suite of infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. The company provides wet utility installations (water, sewer, and stormwater systems), as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services. It derives all revenue in the United States of America from construction projects based in North Carolina and South Carolina.

Share on Social Networks: